ABBVIE
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 2013-01-01
- Employees
- -
- Market Cap
- $346B
- Website
- http://www.abbvie.com
A Study to Assess Adverse Events of Fosigotifator (ABBV-CLS-7262) in Adults With Major Depressive Disorder
- Conditions
- Major Depressive Disorder (MDD)
- Interventions
- Drug: Placebo
- First Posted Date
- 2024-10-01
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 106
- Registration Number
- NCT06618118
- Locations
- 🇺🇸
CenExel CNR /ID# 265866, Sherman Oaks, California, United States
🇺🇸Clinical Neuroscience Solutions - Orlando - East South Street /ID# 265060, Orlando, Florida, United States
🇺🇸CenExel iResearch, LLC /ID# 265886, Decatur, Georgia, United States
A Randomized Trial Assessing Adverse Events and Disease Activity When Comparing Intravenously (IV) Infused ABBV-400 to Trifluridine and Tipiracil (LONSURF) Oral Tablets Plus IV Infused Bevacizumab in Adult Participants With c-Met Over-Expressed Refractory Metastatic Colorectal Cancer
- Conditions
- Metastatic Colorectal Cancer
- Interventions
- First Posted Date
- 2024-09-26
- Last Posted Date
- 2025-04-10
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 460
- Registration Number
- NCT06614192
- Locations
- 🇨🇳
Taipei Veterans General Hospital /ID# 267628, Taipei City, Taiwan
🇨🇳Linkou Chang Gung Memorial Hospital /ID# 267637, Taoyuan City, Taiwan
🇺🇸Winship Cancer Institute of Emory University /ID# 266884, Atlanta, Georgia, United States
Study of Oral ABBV-932 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Bipolar I or II Disorder
- Conditions
- Bipolar I DisorderBipolar II Disorder
- Interventions
- Drug: Placebo for ABBV-932
- First Posted Date
- 2024-09-20
- Last Posted Date
- 2025-02-20
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 160
- Registration Number
- NCT06605599
- Locations
- 🇺🇸
Harmonex /ID# 267504, Dothan, Alabama, United States
🇺🇸Advanced Research Center /ID# 267716, Anaheim, California, United States
🇺🇸Axiom Research /ID# 267518, Colton, California, United States
Post-Marketing Study to Assess the Safety and Effectiveness of Oral Atogepant in Korean Adult Participants for the Prevention of Chronic or Episodic Migraine
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2025-04-10
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 3000
- Registration Number
- NCT06603558
- Locations
- 🇰🇷
Hallym University Dongtan Sacred Heart Hospital /ID# 273581, Hwaseong, Gyeonggido, Korea, Republic of
🇰🇷Yonsei University Health System Severance Hospital /ID# 272639, Seoul, Seoul Teugbyeolsi, Korea, Republic of
🇰🇷Seoul National University Hospital /ID# 271892, Seoul, Seoul Teugbyeolsi, Korea, Republic of
Expanded Access to Fosigotifator
- Conditions
- Vanishing White MatterCree Leukoencephalopathy
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2025-04-04
- Lead Sponsor
- AbbVie
- Registration Number
- NCT06594016
Study to Assess Treatment Patterns and Outcomes With Upadacitinib in Adult Participants With Inflammatory Bowel Disease in Belgium
- Conditions
- Ulcerative ColitisCrohn's Disease
- First Posted Date
- 2024-08-30
- Last Posted Date
- 2025-03-05
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 280
- Registration Number
- NCT06581042
- Locations
- 🇧🇪
Imelda Ziekenhuis /ID# 268631, Bonheiden, Antwerpen, Belgium
🇧🇪CHU de Liège /ID# 267209, Liège, Liege, Belgium
🇧🇪UZ Gent /ID# 268630, Gent, Oost-Vlaanderen, Belgium
A Study to Assess Multiple Ascending Dose, Drug-Drug Interaction, and Asian Pharmacokinetic Study of ABBV-1088
- Conditions
- Healthy Volunteer
- Interventions
- First Posted Date
- 2024-08-30
- Last Posted Date
- 2025-05-20
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 66
- Registration Number
- NCT06579300
- Locations
- 🇺🇸
Acpru /Id# 270552, Grayslake, Illinois, United States
Evaluation of the Safety and Effectiveness of ARTIA Reconstructive Tissue Matrix Breast Reconstruction (ADORA) in Adult Participants
- Conditions
- Breast Reconstruction
- Interventions
- Device: ARTIA Reconstructive Tissue MatrixOther: No Intervention
- First Posted Date
- 2024-08-28
- Last Posted Date
- 2025-05-20
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 783
- Registration Number
- NCT06575192
- Locations
- 🇺🇸
UC Irvine Medical Center /ID# 267428, Orange, California, United States
🇺🇸South Bay Plastic Surgeons /ID# 264192, Torrance, California, United States
🇺🇸Endeavor Health /ID# 266302, Northbrook, Illinois, United States
A Study to Assess the Relative Bioavailability of Two Formulations of Risankizumab Following Subcutaneous Administration With Prefilled Syringes in Healthy Adult Participants
- First Posted Date
- 2024-08-26
- Last Posted Date
- 2025-05-16
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 231
- Registration Number
- NCT06571266
- Locations
- 🇺🇸
Cenexel Act /ID# 270310, Anaheim, California, United States
🇺🇸Collaborative Neuroscience Research CNS /ID# 270286, Los Alamitos, California, United States
🇺🇸Acpru /Id# 270152, Grayslake, Illinois, United States
A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
- First Posted Date
- 2024-08-23
- Last Posted Date
- 2025-05-15
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 150
- Registration Number
- NCT06568939
- Locations
- 🇺🇸
Nebraska Cancer Specialists - Omaha - Wright Street /ID# 271527, Omaha, Nebraska, United States
🇺🇸Cancer Care Associates Of York /ID# 270971, York, Pennsylvania, United States
🇺🇸SCRI Oncology Partners /ID# 270162, Nashville, Tennessee, United States